Nelfinavir

Breastfeeding

See adverse reactions attributed to class:

Antiretroviral

COVID-19 putative drug

HIV-1 protease inhibitor

NOTE

Protease inhibitors cause dyslipidemia which includes elevated triglycerides and cholesterol and redistribution of body fat centrally to produce the so-called 'protease paunch', breast enlargement, facial atrophy, and 'buffalo hump'

Skin

Dermatitis <1%

(package insert)

Diaphoresis <1%

(package insert)

DRESS syndrome 

(1998): Bourezane Y+, Clin Infect Dis 27, 1321

Exanthems 

(1998): Bourezane Y+, Clin Infect Dis 27(5), 1321 (with indinavir)

Hyperhidrosis 

(2000): Bonfanti P+, J Acquir Immune Defic Syndr 23(3), 236

Hypersensitivity 

(1999): Demoly P+, J Allergy Clin Immunol 104 (2 Pt 1), 504

Lichenoid eruption 

(1998): Bourezane Y+, Clin Infect Dis 27(5), 1321

Lipodystrophy 

(2006): Scherpbier HJ+, Pediatrics 117(3), e528

Palmar erythema 

(1998): Bourezane Y+, Clin Infect Dis 27(5), 1321 (with indinavir)

Pruritus (itching) <1%

(package insert)

Rash <10%

(2016): Hill EJ+, Clin Cancer Res 22(8), 1922 (grade 3 / 1 case)

(2008): Moura MD+, J Contemp Dent Pract 9 (1), 84

(2001): Abraham PE+, Ann Pharmacother 35(5), 553

(2000): Fortuny C+, AIDS 14, 335

Urticaria <1%

(1998): Demoly P+, J Allergy Clin Immunol 102(5), 875

Vasculitis 

(1998): Bourezane Y+, Clin Infect Dis 27(5), 1321

Mucosal

Oral ulceration <1%

(package insert)

Cardiovascular
Central Nervous System

Paresthesias <1%

(package insert)

Perioral paresthesias 

(2001): McMahon D+, Antivir Ther 6(2), 105

Vertigo / dizziness 

(2006): Bates DE+, Ann Pharmacother 40(6), 1190 (with carbamazepine)

Endocrine/Metabolic

Gynecomastia 

(2001): Manfredi R+, Ann Pharmacother 35(4), 438

Gastrointestinal/Hepatic

Diarrhea 

(2016): Hill EJ+, Clin Cancer Res 22(8), 1922 (grade 3 / 1 case)

(2014): Alonso-Basanta M+, J Neurooncol 116(2), 365 (with temozolomide and radiotherapy)

(2014): Blumenthal GM+, Oncotarget 5(18), 8161

Hepatotoxicity 

(2014): Alonso-Basanta M+, J Neurooncol 116(2), 365 (with temozolomide and radiotherapy)

(2006): Brown LS+, J Subst Abuse Treat 30(4), 331

(2006): Mira JA+, J Antimicrob Chemother 58(1), 140

Genitourinary

Urolithiasis 

(2014): Izzedine H+, Clin Kidney J 7(2), 121 [REVIEW]

(2002): Engeler DS+, J Urol 167(3), 1384

Hematologic

Anemia 

(2014): Blumenthal GM+, Oncotarget 5(18), 8161

Leukocytopenia (leukopenia) 

(2012): Rengan R+, J Thorac Oncol 7(4), 709 (grade 4 / 6 cases)

Lymphopenia (lymphocytopenia) 

(2016): Hill EJ+, Clin Cancer Res 22(8), 1922 (grade 3 / 1 case)

(2014): Blumenthal GM+, Oncotarget 5(18), 8161

Thrombocytopenia 

(2012): Rengan R+, J Thorac Oncol 7(4), 709 (grade 4 / 1 case)

Neuromuscular/Skeletal

Myalgia/Myositis/Myopathy/Myotoxicity <1%

(package insert)

Rhabdomyolysis 

(2002): Hare CB+, Clin Infect Dis 35(10), e111 (with simvastatin)

Other

Adverse effects 

(2016): Smith C+, Infect Dis Obstet Gynecol Apr, Epub [REVIEW]Pediatric (in infants following maternal ingestion)

Allergic reactions <1%

(package insert)

Death 

(2002): Hare CB+, Clin Infect Dis 35(10), e111 (with simvastatin)



Adverse reactions attributed to entire drug class Antiretroviral

Hematologic

Hematological adverse effect 

(2019): Oumar AA+, Int J Basic Clin Pharmacol 8(5), 83115%

Ocular

Optic neuropathy 

(2013): Wang MY+, J Neuroophthalmol 33(2), 172 [REVIEW]

Other

Adverse effects 

(2019): Oumar AA+, Int J Basic Clin Pharmacol 8(5), 83142%

(2014): Lorio M+, J Int Assoc Provid AIDS Care 13(5), 4666%

Adverse reactions attributed to entire drug class COVID-19 putative drug

Skin

Cutaneous adverse reaction  

(2020): Tursen U+, Dermatol Ther May, Epub ahead of print [REVIEW]

Cardiovascular

Cardiovascular adverse effect 

(2020): Carpenter A+, Front Cardiovasc Med 7, 85 [REVIEW]

(2020): Giudicessi JR+, Mayo Clin Proc May, Online ahead of print [REVIEW]

(2020): Naksuk N+, Eur Heart J Acute Cardiovasc Care May, Epub ahead of print [REVIEW]

(2020): Sarayani A+, Res Social Adm Pharm Apr, Epub ahead of print [REVIEW]

(2020): Zhang D+, Zhongguo Zhong Yao Za Zhi (Chinese) 45(10), 2275-2286 [REVIEW]

Central Nervous System

Neuropsychiatric disturbances 

(2020): García CAC+, Gen Hosp Psychiatry Jun, Online ahead of print [REVIEW]

Gastrointestinal/Hepatic

Gastrointestinal disorder 

(2020): Sun J+, Clin Pharmacol Ther Apr, Epub ahead of print23%

Hepatic disorder 

(2020): Sun J+, Clin Pharmacol Ther Apr, Epub ahead of print14%

Hematologic

Thrombocytopenia 

(2020): Nham E+, Infect Chemother Apr, Epub ahead of print

Other

Adverse effects 

(2020): Favilli A+, J Matern Fetal Neonatal Med Jun, Online ahead of print [REVIEW]

(2020): Griffiths G+, Trials 21(1), 544

(2020): Patil VM+, Life Sci May, Epub ahead of print [REVIEW]

(2020): Rhodes NJ+, medRxiv Jun, Preprint

(2020): Sun J+, Clin Pharmacol Ther Apr, Epub ahead of print38%

(2020): Svensson M, Lakartidningen (Swedish) Apr, 117

(2020): Wen CY+, Zhonghua Nei Ke Za Zhi (Chinese) May, Epub ahead of print

(2020): Zhong H+, Pharmacol Res Apr, Epub ahead of print [REVIEW]

Adverse reactions attributed to entire drug class HIV-1 protease inhibitor

Skin

Eczema 

(2015): Descamps V+, Br J Dermatol 173(1), 311

Xerosis 

(2015): Descamps V+, Br J Dermatol 173(1), 311

Page last updated 06/25/2020

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top